Transaction Overview

Rubicon Research Limited, through its wholly owned subsidiary AdvaGen Holdings' Inc., has acquired a manufacturing facility in East Brunswick, New Jersey, USA from InvaTech Pharma Solutions, LLC. The acquisition was completed on July 21, 2026 at an enterprise value of USD 2.9 million.

Acquisition Details

The transaction was conducted through a court-supervised competitive bid process under Section 363 of the U.S. Bankruptcy Code. The acquisition includes:

  • The manufacturing facility including all equipment, records, and permits associated with the site
  • The existing lease on the property (AdvaGen has entered into a long-term lease on the site)
  • The facility does not include any product approvals or filings

Facility Specifications

The acquired facility:

  • Manufactures oral solid and oral liquid formulations
  • Has been USFDA inspected for over a decade with 3 successful inspections
  • Is approximately the same size as Rubicon's existing facility at Satara, India
  • Shares a wall with Rubicon's US distribution center operated by subsidiary AimRx

Regulatory Status

The USFDA conducted an unannounced inspection of the facility in May 2026, which resulted in:

  • Form 483 issuance with 6 observations
  • Observations were largely procedural in nature and unrelated to data integrity
  • InvaTech has responded to the Form 483 within the prescribed time
  • Corrective actions have been completed as expected by USFDA
  • Rubicon expects the inspection to be successfully concluded in a timely manner

Strategic Intent and Plans

The facility will focus on:

  • Rubicon's specialty and high value products
  • Demand from US government departments

Implementation Timeline

  • Manufacturing of Rubicon products expected to commence in calendar year 2027
  • Requires completion of quality management systems implementation
  • Significant capital investments planned over the next 3 years to expand manufacturing capabilities

Management Commentary

Parag Sancheti, Rubicon's CEO, stated: "The ability to manufacture in the US strongly complements our growing portfolio of branded and specialty products. We value the ability to be closer to our customers and the enhanced agility and resilience this facility brings to our global supply chain. In addition to a strong USFDA inspection history, the site shares a wall with our US distribution center operated by our subsidiary AimRx which enables a unique opportunity for efficient expansion."

Company Background

Rubicon Research Limited is an integrated pharmaceutical company focused on development, manufacturing, and commercialization of differentiated pharmaceutical products. The company has:

  • Portfolio of 80+ pharmaceutical products across multiple therapeutic areas
  • Meaningful portfolio of CNS products
  • Globally inspected manufacturing facilities in India regulated by USFDA, UK MHRA, and Australian TGA
  • R&D organization of over 200 scientists across development centres in Mumbai and Toronto
  • Capabilities spanning research and development, specialty, branded and generic product commercialization